MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 142 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $150,819,304 | -37.4% | 1,032,726 | -1.0% | 0.00% | -42.9% |
| Q2 2023 | $241,057,047 | +4.5% | 1,043,537 | +9.6% | 0.01% | 0.0% |
| Q1 2023 | $230,755,072 | -19.4% | 952,510 | -3.5% | 0.01% | -22.2% |
| Q4 2022 | $286,352,523 | +340.8% | 986,572 | -1.3% | 0.01% | +350.0% |
| Q3 2022 | $64,958,000 | -9.1% | 999,504 | +0.1% | 0.00% | 0.0% |
| Q2 2022 | $71,468,000 | -23.9% | 998,446 | +4.4% | 0.00% | -33.3% |
| Q1 2022 | $93,855,000 | +16.6% | 956,529 | +0.7% | 0.00% | +50.0% |
| Q4 2021 | $80,462,000 | +10.1% | 949,527 | +3.7% | 0.00% | 0.0% |
| Q3 2021 | $73,070,000 | -17.6% | 915,789 | +0.7% | 0.00% | 0.0% |
| Q2 2021 | $88,627,000 | -20.8% | 909,817 | -4.8% | 0.00% | -33.3% |
| Q1 2021 | $111,836,000 | +6.5% | 956,096 | +1.2% | 0.00% | 0.0% |
| Q4 2020 | $104,993,000 | +34.5% | 944,418 | +43.6% | 0.00% | 0.0% |
| Q3 2020 | $78,087,000 | +1.6% | 657,694 | -3.1% | 0.00% | 0.0% |
| Q2 2020 | $76,864,000 | +82.9% | 678,691 | +7.8% | 0.00% | +50.0% |
| Q1 2020 | $42,018,000 | -20.5% | 629,402 | +8.6% | 0.00% | 0.0% |
| Q4 2019 | $52,824,000 | +6.0% | 579,780 | +0.3% | 0.00% | 0.0% |
| Q3 2019 | $49,844,000 | -15.4% | 578,098 | +2.9% | 0.00% | -33.3% |
| Q2 2019 | $58,906,000 | -10.0% | 562,032 | +7.6% | 0.00% | 0.0% |
| Q1 2019 | $65,454,000 | +8.9% | 522,540 | -2.0% | 0.00% | 0.0% |
| Q4 2018 | $60,080,000 | -51.2% | 533,010 | -7.3% | 0.00% | -40.0% |
| Q3 2018 | $123,130,000 | -9.9% | 575,019 | +17.7% | 0.01% | -16.7% |
| Q2 2018 | $136,627,000 | +266.6% | 488,499 | +53.1% | 0.01% | +200.0% |
| Q1 2018 | $37,268,000 | +93.9% | 319,093 | +52.4% | 0.00% | +100.0% |
| Q4 2017 | $19,223,000 | +132.6% | 209,428 | +14.0% | 0.00% | – |
| Q3 2017 | $8,266,000 | +190.6% | 183,778 | +5.1% | 0.00% | – |
| Q2 2017 | $2,844,000 | +1389.0% | 174,882 | +1312.0% | 0.00% | – |
| Q1 2017 | $191,000 | – | 12,385 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |